ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Other EventsItem 8.01
On April 10, 2017, the Company announced that it has scheduled its Annual Meeting of Stockholders (the “Annual Meeting”) to be held at our principal executive offices located at 34790 Ardentech Court, Fremont, California 94555, on May 31, 2017 at 8:30 a.m., Pacific time. The Annual Meeting date has been changed by more than 30 days from the anniversary of the Company’s prior annual meeting of stockholders, which was held on November 2, 2016.
The Bylaws of the Company, as amended, set forth when a stockholder must provide notice to the Company of nominations and other business proposals that the stockholder wants to bring before an annual meeting. Section 5 of the Company’s Bylaws, generally prescribes the procedures that a stockholder of the Company must follow if the stockholder intends (i) to nominate a person for election to the Company’s Board of Directors at an annual meeting of stockholders called for the purpose of electing directors, or (ii) to propose other business to be considered by stockholders at an annual meeting of the stockholders. These procedures include, among other things, that the stockholder give timely notice to the Secretary of the Company of the nomination or other proposed business, that the notice contain specified information, and that the stockholder comply with certain other requirements. In accordance with the Bylaws of the Company, in the event that the date of the annual meeting is advanced more than thirty (30) days prior to the anniversary of the Company’s prior annual meeting of stockholders, notice by the stockholder must be received by the Secretary at the registered office of the Company by the date which is 10 calendar days after the date on which public announcement of the date of the Annual Meeting is first made.
Accordingly, in order for a stockholder nomination or proposal to be considered for inclusion in the Company’s proxy statement for the Annual Meeting, the stockholder must deliver a notice of such nomination or proposal to the Company’s Secretary on or before 5:00 p.m., Pacific Time on Thursday, April 20, 2017, and comply with the requirements of the Company’s Bylaws. Notices should be directed to our Corporate Secretary at Zosano Pharma Corporation, 34790 Ardentech Court, Fremont, California 94555, and should comply with the requirements of Rule 14a-8 under the Securities Exchange Act of 1934, as amended (including the rules and regulations thereunder).
2
About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon. ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Recent Trading Information
ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) closed its last trading session 00.00 at 1.59 with 1,016,953 shares trading hands.